Where does Iovance Biotherapeutics, Inc.'s cash flow data come from?

Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	-$390.98M-5.1%	-$372.18M+16.2%	-$444.04M-12.2%	-$395.89M-15.7%
Depreciation and amortization	$12.68M+3.5%	$12.25M+6.4%	$11.51M+23.6%	$9.31M+199%
Stock-based compensation	$61.58M-43.8%	$109.63M+75.1%	$62.63M-25.5%	$84.02M+20.4%
Deferred income taxes	-$2.26M—	——	-$3.48M—	——
Gain (loss) on sale of assets	——	-$7.36M—	——	-$397K—
Change in accounts receivable	$13.11M-81.1%	$69.19M+46,336%	$149K—	——
Change in inventories	——	$44.38M+324%	$10.47M—	——
Change in accounts payable	-$6.66M—	——	$4.83M-17.9%	$5.88M-15.7%
Change in accrued liabilities	$28.92M+237%	$8.58M-56.6%	$19.77M—	——
Change in other assets	——	——	——	——
Amortization of intangible assets	$23.2M-12.0%	$26.36M+169%	$9.81M—	$0—
Net gains (losses) on investments	——	——	$940K—	——
Non-cash operating lease expense	$11.39M+9.1%	$10.44M-10.9%	$11.71M-1.0%	$11.83M+8.8%
Change in operating lease liabilities	-$10.9M+9.7%	-$12.07M-11.9%	-$10.79M-456%	-$1.94M+67.0%
Net cash from operating activities	-$302.41M+14.3%	-$352.98M+2.4%	-$361.82M-23.6%	-$292.76M-28.4%
Capital expenditures	$33.84M+206%	$11.07M-50.3%	$22.29M+9.1%	$20.43M-45.6%
Purchases of investments	$318.67M-30.8%	$460.77M+124%	$205.9M-16.2%	$245.82M-66.1%
Proceeds from maturities/sales of investments	$400M-6.5%	$428M+49.9%	$285.58M-45.4%	$522.7M-31.5%
Net cash from investing activities	$47.5M—	——	-$155.24M-161%	$256.46M+194,184%
Proceeds from issuance of common stock	$306.31M-22.9%	$397.3M-14.2%	$463.28M+144%	$189.5M-6.7%
Taxes paid for net share settlement	$7.06M-45.1%	$12.86M+360%	$2.8M—	——
Net cash from financing activities	$300.77M-23.0%	$390.66M-15.6%	$462.96M+143%	$190.15M-20.5%
Effect of exchange rate changes on cash	——	-$541K—	——	——
Net increase (decrease) in cash	——	-$59.27M-4.3%	-$56.84M-137%	$153.85M—
Accretion (Amortization) of Discounts and Premiums, Investments	$7.2M-29.8%	$10.26M+175%	$3.73M—	——
Amortization of capitalized software and acquired intangible assets	$23.2M-12.0%	$26.36M+169%	$9.81M—	$0—
Foreign currency remeasurement (loss) gain on debt	$238K—	——	——	——
Gain (Loss) on Disposition of Assets	——	——	——	——
Gain on termination of lease	——	$5.57M—	——	——
Operating lease liabilities	-$10.9M+9.7%	-$12.07M-11.9%	-$10.79M-456%	-$1.94M+67.0%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——
Inventory write-downs	$13.4M—	——	——	——
Operating lease right-of-use asset amortization	$11.39M+9.1%	$10.44M-10.9%	$11.71M-1.0%	$11.83M+8.8%
Proceeds From Sale And Maturity Of Available For Sale Securities	$400M-6.5%	$428M+49.9%	$285.58M-45.4%	$522.7M-31.5%
Acquisitions Of Property And Equipment Included In Accounts Payable And Accrued Expense	——	-$7.37M—	——	-$5.99M—
Exchange Offer (Note 12)	——	——	——	——
Increase Decrease In Operating Lease Liability	-$10.9M+9.7%	-$12.07M-11.9%	-$10.79M-456%	-$1.94M+67.0%
Right Of Use Asset Obtained Reduced In Exchange For Operating Lease Liability From Lease Modifications	——	——	——	——
Unrealized Gain (Loss) on Investments	——	——	$940K—	——
Free cash flow	-$336.24M+7.6%	-$364.05M+5.2%	-$384.11M-22.6%	-$313.18M-18.0%
Free cash flow	-$336.24M+7.6%	-$364.05M+5.2%	-$384.11M-22.6%	-$313.18M-18.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Iovance Biotherapeutics, Inc.'s cash flow data come from?: Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.